Yes, Quviviq (daridorexant) is a Schedule IV controlled substance under the Controlled Substances Act. The Drug Enforcement Administration finalized this classification on September 30, 2022, placing it in the same category as other common sleep medications like zolpidem (Ambien) and suvorexant (Belsomra). This scheduling affects how the medication is prescribed, refilled, and carried when you travel.
Why Quviviq Is Classified as Schedule IV
Quviviq works by blocking orexin receptors in the brain. Orexins are chemical messengers that promote wakefulness, so blocking them turns down your brain’s “stay awake” signal rather than sedating you the way older sleep drugs do. Despite this different mechanism, abuse potential studies showed that at higher-than-prescribed doses, Quviviq produced drug-liking effects similar to zolpidem and suvorexant. Participants in a controlled study rated supratherapeutic doses (two to three times the normal amount) similarly to those older sleep aids on measures like “drug liking,” “feeling high,” and “would take again.”
At the same time, the evidence pointed toward a lower risk profile than substances in Schedules II or III. Animal studies found no signs of physical dependence after 28 days of dosing followed by a two-week discontinuation period. Phase 3 clinical trials in humans also showed no withdrawal symptoms when patients stopped taking Quviviq, and no rebound insomnia, where sleep problems temporarily worsen after stopping a medication. The combination of some psychological appeal at high doses but no physical dependence is a pattern typical of Schedule IV drugs.
What Schedule IV Means for Your Prescription
Schedule IV is less restrictive than Schedules II and III, but it still comes with federal rules that shape how you get and refill Quviviq.
- Refill limits: A single prescription can be refilled up to five times within six months of the date it was written. After five refills or six months (whichever comes first), your prescriber must issue a brand-new prescription.
- No unlimited auto-refills: Unlike non-controlled medications, your pharmacy cannot keep refilling indefinitely. Your doctor can call in additional refills on the original prescription, but the five-refill, six-month cap still applies.
- Prescription records: The pharmacy must log each refill with the date, quantity dispensed, and the initials of the pharmacist who filled it. This tracking is a federal requirement for all Schedule III and IV drugs.
In practice, this means you may need to see your prescriber or at least have a check-in roughly every six months to continue the medication. Some states impose additional restrictions beyond the federal baseline, so your local rules may be slightly tighter.
Traveling With Quviviq
For domestic travel within the United States, keeping Quviviq in its original labeled prescription bottle is the simplest way to avoid problems at airport security or if you’re ever asked about it. Avoid transferring pills into a daily organizer until after you arrive, since loose tablets can’t be easily identified.
International travel requires more preparation. Because Quviviq is a controlled substance in the U.S., it may be restricted or even prohibited in your destination country. The International Narcotics Control Board maintains a list of country-specific rules. Some countries require a certificate from a health authority, while others require documentation issued by the destination country itself. A letter from your doctor listing the medication’s generic name (daridorexant), dosage, and the reason you take it is a practical baseline. Pack the medication in your carry-on rather than checked luggage to reduce the risk of loss, damage, or questions arising when you’re not present.
Abuse and Dependence Risk in Practice
The Schedule IV label can sound alarming, but context matters. At the recommended dose of 25 mg or 50 mg taken within 30 minutes of bedtime, clinical trials did not show the same drug-liking effects that appeared at double or triple that amount. The abuse potential findings came specifically from supratherapeutic doses given under controlled research conditions.
Physical dependence was not observed in any clinical study. Researchers assessed withdrawal using a standardized questionnaire originally designed for benzodiazepine withdrawal and found no signal at any tested dose, including 10 mg, 25 mg, and 50 mg. Patients who stopped Quviviq did not experience a return of worse-than-baseline insomnia, which is a notable difference from some older sleep medications where rebound insomnia is a recognized concern.
Psychological dependence is harder to rule out entirely, which is partly why the Schedule IV designation exists. The human abuse potential study confirmed that Quviviq can produce pleasurable subjective effects at high doses, similar to what zolpidem and suvorexant produce. This doesn’t mean most patients will develop a problem, but it does mean the medication carries enough appeal at elevated doses to warrant monitoring and controlled dispensing.
How Quviviq Compares to Other Sleep Medications
Quviviq sits in the same DEA schedule as most other prescription sleep aids. Zolpidem, zaleplon, eszopiclone, suvorexant, and lemborexant are all Schedule IV. The main pharmacological difference is that Quviviq and the other orexin blockers (suvorexant and lemborexant) work by quieting wakefulness signals rather than amplifying the brain’s sedation pathways the way older Z-drugs do. In clinical discontinuation data, this translates to a cleaner stop: no withdrawal symptoms and no rebound insomnia, which some patients on Z-drugs do experience.
From a prescription standpoint, the practical experience is identical across Schedule IV sleep medications. The same refill limits, the same pharmacy tracking requirements, and the same travel considerations apply regardless of which one you take.